Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience

Journal of Assisted Reproduction and Genetics

Volumn 33, Issue 10, 2016, Pages 1311-1318

  Andersen, C Yding ^a,b   Fischer, R ^c   Giorgione, V ^a   Kelsey, Thomas W ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c Amedes MVZ Hamburg   (Germany)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Corpus luteum function; GnRH agonist trigger; hCG; Luteal phase support

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; LIPOPOLYSACCHARIDE; LUTEINIZING HORMONE RECEPTOR; PROGESTERONE; FOLLITROPIN;

ARTICLE; CHEMICAL STRUCTURE; CIRCULATION; CLINICAL EVALUATION; CLINICAL PROTOCOL; COCHRANE LIBRARY; CONCENTRATION PROCESS; ENDOMETRIUM; HORMONE RELEASE; HUMAN; LUTEAL PHASE; LUTEAL PHASE SUPPORT; MATHEMATICAL MODEL; NIDATION; OOCYTE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; IN VITRO FERTILIZATION; IN VITRO OOCYTE MATURATION; OVARY FOLLICLE; OVULATION; OVULATION INDUCTION; PREGNANCY; PROCEDURES; THEORETICAL MODEL;

CHORIONIC GONADOTROPIN; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; IN VITRO OOCYTE MATURATION TECHNIQUES; LUTEAL PHASE; MODELS, THEORETICAL; OVARIAN FOLLICLE; OVULATION; OVULATION INDUCTION; PREGNANCY; PROGESTERONE;

EID: 84979587870     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-016-0764-7     Document Type: Article

References (29)

1. Mathur RS, Akande VA, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901–9.
2. Papanikolaou EG, Pozzobon C, Kolibianakis EM. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112–20.
3. Aboulghar M. Symposium: update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online. 2009;19:33–42.
4. Papanikolaou EG, Humaidan P, Polyzos NP, Tarlatzis B. Identification of the high-risk patient for ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28:458–62.
5. Fauser BC, De Jong D, Loivennes F, Wramsby H, Tay C, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist Ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002;87:709–15.
6. Yding Andersen C, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, et al. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. Hum Reprod. 2015;30:2387–95.
7. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213–20.
8. Humaidan P, Bungum L, Bungum M, Yding AC. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online. 2006;13:173–8.
9. Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod. 2013;28:2511–21.
10. Humaidan P, Kol S, Papanikolaou EG. Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17:510–24.
11. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887–92.
12. Liu HC, Pyrgiotis E, Davis O, Rosenwaks Z. Active corpus luteum function at pre-, peri- and postimplantation is essential for a viable pregnancy. Early Pregnancy. 1995;1:281–7.
13. Yovich JL, Conceicao JL, Stanger JD, Hinchliffe PM, Keane KN. Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement. Reprod Biomed Online. 2015;31:180–91.
14. Yding Andersen C, Vilbour AK. Improving the luteal phase after ovarian stimulation: reviewing new options. Reprod Biomed Online. 2014;28:552–9.
15. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7:CD009154.
16. Kupferminc MJ, Lessing JB, Amit A, Yovel I, David MP, et al. A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer. Hum Reprod. 1990;5:271–3.
17. Trinchard-Lugan I, Khan A, Porchet HC, Munafo A. Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. Reprod Biomed Online. 2002;4:106–15.
18. Evans J, Salamonsen LA. Too much of a good thing? Experimental evidence suggests prolonged exposure to hCG is detrimental to endometrial receptivity. Hum Reprod. 2013;28:1610–9.
19. Cole LA. hCG, five independent molecules. Clin Chim Acta. 2012;413:48–65.
20. Fournier T, Guibourdenche J, Evain-Brion D. hCGs: different sources of production, different glycoforms and functions. Placenta. 2015;36:S60–5.
21. Cole LA. hCG, the wonder of today’s science. Reprod Biol Endocrinol. 2012;10:24.
22. Cole LA. Hyperglycosylated hCG and pregnancy failures. J Reprod Immunol. 2012;93:119–22.
23. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril. 2011;95:1174–7.
24. Abecia JA, Lozano JM, Forcada F, Zarazaga L. Effect of level of dietary energy and protein on embryo survival and progesterone production on day eight of pregnancy in Rasa Aragonesa ewes. Anim Reprod Sci. 1997;48:209–18.
25. Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8 % administered vaginally versus prometrium administered orally in postmenopausal women. Fertil Steril. 2000;73:516–21.
26. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–6.
27. Filicori M, Butler JP, Crowley Jr WF. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest. 1984;73:1638–47.
28. Thuesen LL, Loft A, Egeberg AN, Smitz J, Petersen JH, Andersen AN. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod. 2012;27:3074–84.
29. Castillo JC, Dolz M, Bienvenido E, Abad L, Casañ EM, et al. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online. 2010;20:175–81.